Another vv, mJX-594, armed with granulocyte-macrophage-colony-stimulating factor (GM-CSF) also had higher anticancer immunity when combined with the immune checkpoint inhibitors anti-PD-1, anti-PD-L1, and anti-LAG3 when used to treat CRC (MC38 cells, mouse model, IP delivery), PM, and malignant ascites. Here, CSF2 is linked to colorectal carcinoma.